Literature DB >> 8935797

Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

B J Kinon1, J A Lieberman.   

Abstract

Various criteria used to define atypical antipsychotic drugs include: 1) decrease, or absence, of the capacity to cause acute extrapyramidal motor side effects (acute EPSE) and tardive dyskinesia (TD); 2) increased therapeutic efficacy reflected by improvement in positive, negative, or cognitive symptoms; 3) and a decrease, or absence, of the capacity to increase prolactin levels. The pharmacologic basis of atypical antipsychotic drug activity has been the target of intensive study since the significance of clozapine was first appreciated. Three notions have been utilized conceptually to explain the distinction between atypical versus typical antipsychotic drugs: 1) dose-response separation between particular pharmacologic functions; 2) anatomic specificity of particular pharmacologic activities; 3) neurotransmitter receptor interactions and pharmacodynamics. These conceptual bases are not mutually exclusive, and the demonstration of limbic versus extrapyramidal motor functional selectivity is apparent within each arbitrary theoretical base. This review discusses salient distinctions predominantly between prototypic atypical and typical antipsychotic drugs such as clozapine and haloperidol, respectively. In addition, areas of common function between atypical and typical antipsychotic drug action may also be crucial to our identification of pathophysiological foci of the different dimensions of schizophrenia, including positive symptoms, negative symptoms, and neurocognitive deficits.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935797     DOI: 10.1007/bf02245602

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  463 in total

1.  Differences in dopamine release and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis.

Authors:  W T O'Connor; K L Drew; U Ungerstedt
Journal:  Neurosci Lett       Date:  1989-03-27       Impact factor: 3.046

2.  Neuroleptics have identical potencies in human brain limbic and putamen regions.

Authors:  P Seeman; C Ulpian
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

3.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine.

Authors:  M H Chakos; J A Lieberman; J Alvir; R Bilder; M Ashtari
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

4.  Dopamine D4 receptor variants in unrelated schizophrenic cases and controls.

Authors:  S S Sommer; T J Lind; L L Heston; J L Sobell
Journal:  Am J Med Genet       Date:  1993-07-15

5.  Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.

Authors:  M M Pinter; R J Helscher
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1993

6.  Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol.

Authors:  M Kuoppamäki; T Seppälä; E Syvälahti; J Hietala
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

7.  Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias.

Authors:  M F Egan; Y Hurd; T M Hyde; D R Weinberger; R J Wyatt; J E Kleinman
Journal:  Synapse       Date:  1994-11       Impact factor: 2.562

8.  Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats.

Authors:  R E See; A W Toga; G Ellison
Journal:  J Neural Transm Gen Sect       Date:  1990

9.  A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.

Authors:  Y D Lapierre; N P Nair; G Chouinard; A G Awad; B Saxena; B Jones; D J McClure; D Bakish; P Max; R Manchanda
Journal:  Acta Psychiatr Scand Suppl       Date:  1990

10.  Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred.

Authors:  F Macciardi; A Petronis; H H Van Tol; C Marino; M C Cavallini; E Smeraldi; J L Kennedy
Journal:  Arch Gen Psychiatry       Date:  1994-04
View more
  48 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 2.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 3.  How human electrophysiology informs psychopharmacology: from bottom-up driven processing to top-down control.

Authors:  J Leon Kenemans; Seppo Kähkönen
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

4.  Spotlight on olanzapine in bipolar I disorder.

Authors:  Paul L McCormack; Lynda R Wiseman
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

Review 6.  The 'atypicality' of antipsychotics: a concept re-examined and re-defined.

Authors:  Gerhard Gründer; Hanns Hippius; Arvid Carlsson
Journal:  Nat Rev Drug Discov       Date:  2009-02-13       Impact factor: 84.694

7.  Risk/reward decision-making in schizophrenia: a preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performance.

Authors:  Sarah W Yip; Kristi A Sacco; Tony P George; Marc N Potenza
Journal:  Schizophr Res       Date:  2009-03-09       Impact factor: 4.939

8.  Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway.

Authors:  Ornella Valenti; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-15       Impact factor: 5.176

9.  Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission.

Authors:  P V Piazza; M Barrot; F Rougé-Pont; M Marinelli; S Maccari; D N Abrous; H Simon; M Le Moal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

10.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.

Authors:  D E Adkins; K Aberg; J L McClay; J Bukszár; Z Zhao; P Jia; T S Stroup; D Perkins; J P McEvoy; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2010-03-02       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.